Discovery and development of DNA methylation-based biomarkers for lung cancer

Epigenomics

Volumn 6, Issue 1, 2014, Pages 59-72

  Walter, Kimberly ^a   Holcomb, Thomas ^a   Januario, Tom ^a   Yauch, Robert L ^a   Du, Pan ^a   Bourgon, Richard ^a   Seshagiri, Somasekar ^a   Amler, Lukas C ^a   Hampton, Garret M ^a   Shames, David S ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MICRORNA 200C; UNTRANSLATED RNA;

AMPLICON; CANCER RESEARCH; CANCER SURVIVAL; CHROMATIN STRUCTURE; CONSTITUTIVE HETEROCHROMATIN; CPG ISLAND; DNA METHYLATION; DNA REPLICATION; DNA SEQUENCE; EPIGENETICS; EUKARYOTIC CELL; GENE EXPRESSION; GENE SILENCING; HETEROCHROMATIN; HIGH THROUGHPUT SCREENING; HISTONE MODIFICATION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMOTER REGION; PYROSEQUENCING; REVIEW; RNA SEQUENCE; SURVIVAL RATE; TRANSCRIPTION REGULATION;

CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIGH-THROUGHPUT SCREENING ASSAYS; HISTONES; HUMANS; LUNG NEOPLASMS; REPRODUCIBILITY OF RESULTS; RNA, UNTRANSLATED; TUMOR MARKERS, BIOLOGICAL;

EID: 84895456119     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.13.81     Document Type: Review

References (73)

1. Baylin SB. The cancer epigenome: Its origins, contributions to tumorigenesis, and translational implications. Proc. Am. Thorac. Soc. 9(2), 64-65 (2012
2. Weichenhan D, Plass C. The evolving epigenome. Hum. Mol. Genet. 22(R1), R1-R6 (2013
3. Baer C, Claus R, Plass C. Genome-wide epigenetic regulation of miRNAs in cancer. Cancer Res. 73(2), 473-477 (2013
4. Melo SA, Esteller M. Dysregulation of microRNAs in cancer: Playing with fire. FEBS Lett. 585(13), 2087-2099 (2011
5. Gantier MP, Mccoy CE, Rusinova I et al. Analysis of microRNA turnover in mammalian cells following Dicer1 ablation. Nucleic Acids Res. 39(13), 5692-5703 (2011
6. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: Approaches and considerations. Nat. Rev. Genet. 13(5), 358-369 (2012
7. Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18(10), 997-1006 (2008
8. Cai J, Wu J, Zhang H et al. miR-186 downregulation correlates with poor survival in lung adenocarcinoma, where it interferes with cell-cycle regulation. Cancer Res. 73(2), 756-766 (2013
9. Cao J, Song Y, Bi N et al. DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer. Cancer Res. 73(11), 3326-3335 (2013
10. Liloglou T, Bediaga NG, Brown BR, Field JK, Davies MP. Epigenetic biomarkers in lung cancer. Cancer Lett. 342(2), 200-212 (2012
11. Zhu X, Li Y, Shen H et al. miR-137 inhibits the proliferation of lung cancer cells by targeting Cdc42 and Cdk6. FEBS Lett. 587(1), 73-81 (2013
12. Wang Z, Chen Z, Gao Y et al. DNA hypermethylation of microRNA-34b/c has prognostic value for stage non-small cell lung cancer. Cancer Biol. Ther. 11(5), 490-496 (2011
13. Tanaka N, Toyooka S, Soh J et al. Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer. Lung Cancer 76(1), 32-38 (2012
14. Heller G, Weinzierl M, Noll C et al. Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers. Clin. Cancer Res. 18(6), 1619-1629 (2012
15. Ceppi P, Mudduluru G, Kumarswamy R et al. Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol. Cancer Res. 8(9), 1207-1216 (2010
16. Tellez CS, Juri DE, Do K et al. EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res. 71(8), 3087-3097 (2011
17. Walter K, Holcomb T, Januario T et al. DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer. Clin. Cancer Res. 18(8), 2360-2373 (2012
18. Roybal JD, Zang Y, Ahn YH et al. miR-200 inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1. Mol. Cancer Res. 9(1), 25-35 (2011
19. Allis CD, Jenuwein T, Reinberg D. Epigenetics. Cold Spring Harbor Laboratory Press, NY, USA (2007
20. Easwaran H, Johnstone SE, Van Neste L et al. A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res. 22(5), 837-849 (2012
21. You JS, Jones PA Cancer genetics and epigenetics: Two sides of the same coin? Cancer Cell 22(1), 9-20 (2012
22. Liu J, Lee W, Jiang Z et al. Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res. 22(12), 2315-2327 (2012
23. Rodriguez-Paredes M, Martinez De Paz A, Simo-Riudalbas L et al. Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis. Oncogene doi:10.1038/onc.2013.239 (2013
24. Reisman D, Glaros S, Thompson EA. The SWI/SNF complex and cancer. Oncogene 28(14), 1653-1668 (2009
25. Kurdistani SK. Histone modifications in cancer biology and prognosis. Prog. Drug Res. 67, 91-106 (2011
26. Seligson DB, Horvath S, Mcbrian MA et al. Global levels of histone modifications predict prognosis in different cancers. Am. J. Pathol. 174(5), 1619-1628 (2009
27. Reisman DN, Sciarrotta J, Wang W, Funkhouser WK, Weissman BE. Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: Correlation with poor prognosis. Cancer Res. 63(3), 560-566 (2003
28. Fukuoka J, Fujii T, Shih JH et al. Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin, Cancer Res. 10(13), 4314-4324 (2004
29. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 17(3), 330-339 (2011
30. Shames DS, Elkins K, Walter K et al. Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors. Clin. Cancer Res. 19 (24) 6912-6923 (2013
31. Fujii M, Fujimoto N, Hiraki A et al. Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma. Cancer Sci. 103(3), 510-514 (2012
32. Schmidt B, Liebenberg V, Dietrich D et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer 10, 600 (2010
33. Kneip C, Schmidt B, Seegebarth A et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J. Thorac. Oncol. 6(10), 1632-1638 (2011
34. Lokk K, Vooder T, Kolde R et al. Methylation markers of early-stage non-small cell lung cancer. PLoS ONE 7(6), e39813 (2012
35. Lockwood WW, Wilson IM, Coe BP et al. Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development. PloS ONE 7(5), e37775 (2012
36. Selamat SA, Chung BS, Girard L et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res. 22(7), 1197-1211 (2012
37. De Fraipont F, Levallet G, Creveuil C et al. An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial. Clin. Cancer Res. 18(10), 2976-2986 (2012
38. Brock MV, Hooker CM, Ota-Machida E et al. DNA methylation markers and early recurrence in stage I lung cancer. N. Engl. J. Med. 358(11), 1118-1128 (2008
39. Tessema M, Yingling CM, Thomas CL et al. SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15. Oncogene 31(37), 4107-4116 (2012
40. Cortes-Sempere M, De Miguel MP, Pernia O et al. IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer. Oncogene 32(10), 1274-1283 (2013
41. Balgkouranidou I, Liloglou T, Lianidou ES. Lung cancer epigenetics: Emerging biomarkers. Biomarkers Med. 7(1), 49-58 (2013
42. Toyooka S, Gazdar AF. Methylation profiling of lung cancer: A decade of progress. Mol. Cancer Ther. 10(11), 2020 (2011
43. Zuo T, Tycko B, Liu TM, Lin JJ, Huang TH. Methods in DNA methylation profiling. Epigenomics 1(2), 331-345 (2009
44. Feinberg AP. Genome-scale approaches to the epigenetics of common human disease. Virchows Arch. 456(1), 13-21 (2010
45. Bock C, Tomazou EM, Brinkman AB et al. Quantitative comparison of genome-wide DNA methylation mapping technologies. Nat. Biotechnol. 28(10), 1106-1114 (2010
46. Cokus SJ, Feng S, Zhang X et al. Shotgun bisulphite sequencing of the Arabidopsis genome reveals DNA methylation patterning. Nature 452(7184), 215-219 (2008
47. Lister R, Ecker Jr. Finding the fifth base: Genome-wide sequencing of cytosine methylation. Genome Res. 19(6), 959-966 (2009
48. Lister R, O'Malley RC, Tonti-Filippini J et al. Highly integrated single-base resolution maps of the epigenome in Arabidopsis. Cell 133(3), 523-536 (2008
49. Lister R, Pelizzola M, Dowen RH et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462(7271), 315-322 (2009
50. Sandoval J, Heyn H, Moran S et al. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics 6(6), 692-702 (2011
51. Touleimat N, Tost J. Complete pipeline for Infinium((R)) Human Methylation 450K BeadChip data processing using subset quantile normalization for accurate DNA methylation estimation. Epigenomics 4(3), 325-341 (2012
52. Hansen KD, Timp W, Bravo HC et al. Increased methylation variation in epigenetic domains across cancer types. Nat. Genet. 43(8), 768-775 (2011
53. Irizarry RA, Ladd-Acosta C, Wen B et al. The human colon cancer methylome shows similar hypo-And hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 41(2), 178-186 (2009
54. Bock C. Analysing and interpreting DNA methylation data. Nat. Rev. Genet. 13(10), 705-719 (2012
55. Ivanov M, Kals M, Kacevska M, Metspalu A, Ingelman-Sundberg M, Milani L. In-solution hybrid capture of bisulfite-converted DNA for targeted bisulfite sequencing of 174 ADME genes. Nucleic Acids Res. 41(6), e72 (2013
56. Smith ZD, Gu H, Bock C, Gnirke A, Meissner A. High-Throughput bisulfite sequencing in mammalian genomes. Methods 48(3), 226-232 (2009
57. Meissner A, Gnirke A, Bell GW, Ramsahoye B, Lander ES, Jaenisch R. Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. Nucleic Acids Res. 33(18), 5868-5877 (2005
58. Boyle P, Clement K, Gu H et al. Gel-free multiplexed reduced representation bisulfite sequencing for large-scale DNA methylation profiling. Genome Biol. 13(10), R92 (2012
59. Ziller MJ, Gu H, Muller F et al. Charting a dynamic DNA methylation landscape of the human genome. Nature 500(7463), 477-481 (2013
60. Ostrow KL, Hoque MO, Loyo M et al. Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR. Clin. Cancer Res. 16(13), 3463-3472 (2010
61. Migheli F, Stoccoro A, Coppede F et al. Comparison study of MS-HRM and pyrosequencing techniques for quantification of APC and CDKN2A gene methylation. PloS ONE 8(1), e52501 (2013
62. Markopoulou S, Nikolaidis G, Liloglou T. DNA methylation biomarkers in biological fluids for early detection of respiratory tract cancer. Clin. Chem. Lab. Med. 50(10), 1723-1731 (2012
63. Begum S, Brait M, Dasgupta S et al. An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin. Cancer Res. 17(13), 4494-4503 (2011
64. Guzman L, Depix MS, Salinas AM et al. Analysis of aberrant methylation on promoter sequences of tumor suppressor genes and total DNA in sputum samples: A promising tool for early detection of COPD and lung cancer in smokers. Diagn. Pathol. 7, 87 (2012
65. Leng S, Do K, Yingling CM et al. Defining a gene promoter methylation signature in sputum for lung cancer risk assessment. Clin. Cancer Res. 18(12), 3387-3395 (2012
66. Li M, Chen WD, Papadopoulos N et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat. Biotechnol. 27(9), 858-863 (2009
67. Garcia-Gimenez JL, Sanchis-Gomar F, Lippi G et al. Epigenetic biomarkers: A new perspective in laboratory diagnostics. Clin. Chimica Acta 413(19-20), 1576-1582 (2012
68. Hurteau GJ, Carlson JA, Spivack SD, Brock GJ. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res. 67(17), 7972-7976 (2007
69. Vrba L, Garbe JC, Stampfer MR, Futscher BW. Epigenetic regulation of normal human mammary cell type-specific miRNAs. Genome Res. 21(12), 2026-2037 (2011
70. Doi A, Park IH, Wen B et al. Differential methylation of tissue-And cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nature Genet. 41(12), 1350-1353 (2009
71. Wu H, Caffo B, Jaffee HA, Irizarry RA, Feinberg AP. Redefining CpG islands using hidden Markov models. Biostatistics 11(3), 499-514 (2010
72. Bediaga NG, Davies MP, Acha-Sagredo A et al. A microRNA-based prediction algorithm for diagnosis of non-small lung cell carcinoma in minimal biopsy material. Br. J. Cancer 456(1), 13-21 (2013
73. Nikolaidis G, Raji OY, Markopoulou S et al. DNA methylation biomarkers offer improved diagnostic efficiency in lung cancer. Cancer Res. 72(22), 5692-5701 (2012